| A Case of Pituitary Macroadenoma Concurrently Diagnosed in a Patient Undergoing Antipsychotic Treatment |
|
Bong Sun Kim, Joo Sung Kim, Hyong Kyu Ryu, Jin Woong Park, Sun A Hyun, Je Wook Kang, Yong Jun Choi |
|
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea |
| 항정신병 약제 치료 중 동반된 프로락틴 분비 뇌하수체 거대선종 치료 1예 |
|
김봉선, 김주성, 류형규, 박진웅, 현선아, 강제욱, 최용준 |
|
아주대학교 의과대학 내분비대사내과학교실 |
Correspondence:
Yong Jun Choi, Tel: +82-31-219-4491, Fax: +82-31-219-4497, Email: colsmile@hanmail.net
|
|
Received: 23 January 2014 • Revised: 26 May 2014 • Accepted: 27 June 2014 |
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
| Abstract |
|
Antipsychotics are the drug of choice for patients with schizophrenia, but they can induce hyperprolactinemia and growth of pituitary adenomas by blocking dopamine 2 receptors in the pituitary gland. In contrast, the medical treatment for a prolactinoma is a dopamine agonist. Therefore, managing a patient concurrently diagnosed with a prolactinoma and psychosis is challenging. We describe a patient with schizophrenia who was diagnosed with a prolactinoma. We changed his neuroleptic to quetiapine and prescribed bromocriptine for the prolactinoma. As a result, the patient was successfully treated with a dopamine agonist and antipsychotic without psychotic exacerbation. Our case suggests that dopamine agonists can be administrated to patients with schizophrenia and a prolactinoma without adversely affecting their psychopathological status. |
| Key Words:
Prolactinoma; Bromocriptine; Antipsychotic agents |
|
PDF Links
Full text via DOI
Download Citation
